Article Information
History
- March 6, 2025.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Eric Milan Mukherjee, MD PhD1,2,
- Dodie Park2,
- Michelle Martin-Pozo, PhD2,3 and
- Elizabeth Phillips, MD2,3,4,*
- 1Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
- 2Center for Drug Safety and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
- 3Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee, USA
- 4Institute for Immunology and Infectious Diseases, Murdoch University, Perth, Australia
- ↵*Corresponding author: elizabeth.j.phillips{at}vumc.org
Posted March 06, 2025.
Characterization of Demographics, Drug Latency, and Mortality of Severe Cutaneous Adverse Reactions in an FDA Pharmacovigilance Database
